PXL SAPPHIRE 318: Advanced Corneal Cross-Linking Technology
. PXL SAPPHIRE 318 is the latest innovation in corneal cross-linking (CXL),a non-invasive and highly effective treatment for progressive keratoconus and other ectatic corneal diseases.
With swiss quality and cutting-edge technology, PXL SAPPHIRE 318 redefines the way corneal cross-linking is performed, offering a safe, fast and effective treatment.
Discover the future of keratoconus treatment with PXL SAPPHIRE 318
Main Advantages:
✔ Efficient and Safe – Clinically proven to stabilise the progression of keratoconus and regularise the cornea.
✔ Treatment Flexibility – Four energy levels (3mW - 18mW) and continuous, interval and LASIK modes.
✔ High-Precision - Automatic system calibration and continuous aperture adjustment (3 mm to 12 mm) to protect limbal stem cells.
✔ Portable and Intuitive – Compact design with table mounting and 5″ colour touchscreen for easy operation.
✔ Versatile Use – In addition to treating ectatic diseases, the CXL is also a promising alternative for infectious keratitis, reducing dependence on antibiotics.
Goldfarma Comércio de Produtos Farmacêuticos Lda., has notified Infarmed within the scope of the exercise of the activities of Distribution of Medicines and Medical Devices. NIPC 507372328
Goldfarma Comércio de Produtos Farmacêuticos Lda., has notified Infarmed within the scope of the exercise of the activities of Distribution of Medicines and Medical Devices. NIPC 507372328
goldfarma © 2025 all rights reserved
